![](/images/graphics-bg.png)
A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review
Joint Authors
Kakimoto, Tomoo
Sasaki, Mamoru
Yamamoto, Tatsuya
Iwamaru, Arifumi
Ogata, Kentaro
Lee, Ko
Nakayama, Shingo
Minematsu, Naoto
Source
Case Reports in Oncological Medicine
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-5, 5 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-10-15
Country of Publication
Egypt
No. of Pages
5
Main Subjects
Abstract EN
We previously reported a case of giant cell carcinoma in the lung, in which the use of antiprogrammed death 1 (PD-1) immunotherapy resulted in substantial tumor reduction.
In the present study, we describe an additional clinical course.
A 69-year-old woman was diagnosed with giant cell carcinoma of the lung in clinical stage IVB (T2bN0M1c, BRA).
The tumor expressed programmed death ligand 1 (PD-L1) in a high proportion.
The patient received stereotactic radiotherapy for two sites of small brain metastases, followed by immunotherapy using anti-PD-1 antibodies (pembrolizumab).
The treatment exerted a substantial tumor reduction through four cycles.
However, treatment was withdrawn due to renal dysfunction.
The primary lung tumor continued to regress for an additional four months without any further therapy, resulting in a clinical stage of T1aN0M0.
Salvage thoracic surgery was then performed to remove the tumor residue in the lung.
Microscopic examination of the sample revealed no residual cancer.
The patient was free from recurrence at 16 months post surgery.
We then comprehensively reviewed lung sarcomatoid carcinoma cases in the literature, in which anti-PD-1 antibodies were implemented.
The current literature and our own findings suggest sarcomatoid carcinomas express high levels of tumoral PD-L1 and can be effectively treated with anti-PD-1 antibodies.
American Psychological Association (APA)
Kakimoto, Tomoo& Sasaki, Mamoru& Yamamoto, Tatsuya& Iwamaru, Arifumi& Ogata, Kentaro& Lee, Ko…[et al.]. 2019. A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review. Case Reports in Oncological Medicine،Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141847
Modern Language Association (MLA)
Kakimoto, Tomoo…[et al.]. A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review. Case Reports in Oncological Medicine No. 2019 (2019), pp.1-5.
https://search.emarefa.net/detail/BIM-1141847
American Medical Association (AMA)
Kakimoto, Tomoo& Sasaki, Mamoru& Yamamoto, Tatsuya& Iwamaru, Arifumi& Ogata, Kentaro& Lee, Ko…[et al.]. A Histologically Complete Response to Immunotherapy Using Pembrolizumab in a Patient with Giant Cell Carcinoma of the Lung: An Additional Report and Literature Review. Case Reports in Oncological Medicine. 2019. Vol. 2019, no. 2019, pp.1-5.
https://search.emarefa.net/detail/BIM-1141847
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1141847